相关实验视频
Updated: Jun 3, 2025

10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
32.0K
西塔格利普丁眼滴的眼睛和血药动力学:临床前数据
Cristina Hernández1,2,3, Hugo Ramos1,2, Anne Létondor4
1Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.
Pharmaceuticals (Basel, Switzerland)
|January 8, 2025
概括
西塔格利普丁眼滴有效地治疗早期糖尿病视网膜病变,通过到达视网膜而没有显著的系统吸收. 这种局部方法为视网膜疾病提供了新的治疗选择.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 早期糖尿病视网膜病变是一种未满足的医疗需求,治疗选择有限.
- 西塔格利普丁眼液在早期糖尿病视网膜病变中有望预防神经退行和微血管损伤.
- 这些效应发生在没有改善全身葡萄糖水平的情况下.
研究的目的:
- 为了研究西塔格利普丁眼滴的药理动力学和眼部分布.
- 为了确定药物的吸收路径和全身暴露.
主要方法:
- 在新西兰子上局部注射西塔利普丁眼滴 (5 mg/mL和10 mg/mL).
- 在不同时间点 (10分钟至24小时) 采集眼睛和血样本.
- 使用液体染色学-并联质谱法 (LC-MS/MS) 量化西塔利普丁度的分析.
主要成果:
- 西塔利普丁在水性和玻璃性水分之前就已经到达视网膜.
- 吸收似乎遵循了穿关的路线.
- 系统吸收是最小的,低于药理活性水平.
结论:
- 西塔格利普丁眼液在治疗视网膜疾病方面表现出良好的眼部药理动力学.
- 穿越质路径有助于将药物输送到视网膜.
- 局部西塔利普丁是一种可行的治疗策略,用于糖尿病视网膜病变和其他视网膜疾病.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
Open Angle Glaucoma: Treatment
391
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
391
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136

